NCT03683004 is a clinical trial in Colorectal Cancer, sponsored by University of Nebraska.

Who is sponsoring NCT03683004?

NCT03683004 is sponsored by University of Nebraska.

What condition does NCT03683004 study?

NCT03683004 studies Colorectal Cancer.

Is NCT03683004 still recruiting?

NCT03683004 is currently completed. Last updated 29 September 2023.

Last reviewed 2023-09-29 · How we verify

NCT03683004

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chemotherapy-Related Changes in Neurocognitive Function and Symptoms in Colorectal Cancer Patients: A Pilot Study

Completed Last updated 29 September 2023

What this trial tests

trial in Colorectal Cancer in 40 participants. Completed in 25 November 2020.

Timeline

22 January 2018

Primary endpoint
25 November 2020

25 November 2020

Quick facts

Lead sponsor	University of Nebraska
Status	Completed
Study type	OBSERVATIONAL
Enrollment	40
Start date	22 January 2018
Primary completion	25 November 2020
Estimated completion	25 November 2020
Sites	1 location across United States

Conditions studied

Colorectal Cancer — all drugs for Colorectal Cancer →

Sponsor

University of Nebraska

Who can join

19 and older, any sex, with Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cancer treatments have successfully improved cancer outcomes but frequently negatively impact quality of life in cancer survivors. In particular, chemotherapy (CTX) has been associated with impaired cognitive abilities such as concentration and memory. The goal is to investigate the neural mechanisms of chemotherapy-related cognitive impairment (CRCI) using an interdisciplinary translational approach. Previous research in this area lacks diversity in studied cancer populations and treatments focusing primarily on breast cancer and provides limited understanding of how CRCI emerges from changes in neural structure, function, and connectivity. To overcome these limitations, this feasibility/pilot study aims to investigate CRCI in patients with colorectal cancer (CRC).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Neurocognitive function and quality-of-life in patients with colorectal cancer.
Berger AM, Grem J, Garlinghouse M, Lyden E, et al · · 2023 · cited 4× · PMID 37137248 · DOI 10.1016/j.ejon.2023.102304

Verify or expand the search:

Other recruiting trials for Colorectal Cancer

Currently open trials in the same condition.

NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting

Other University of Nebraska trials

Trials by the same sponsor.

NCT07507006 — Feasibility Study of the Flash-Sole: A Wearable Midsole With Soft Actuators for Walking Assistance · NA · not yet recruiting
NCT07517705 — MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma · NA · not yet recruiting
NCT07506993 — Inflammation in Clear Aligners With and Without Attachments · not yet recruiting
NCT07207850 — Parents Helping Parents for Youth Vaping Cessation · NA · not yet recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03683004 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Nebraska
Last refreshed: 29 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03683004.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing